Adicet Bio, Inc. (LON: 0HX7)
London
· Delayed Price · Currency is GBP · Price in USD 0.915
-0.022 (-2.40%)
At close: Jan 22, 2025
Adicet Bio Employees
Adicet Bio had 143 employees as of December 30, 2023. The number of employees increased by 11 or 8.33% compared to the previous year.
Employees
143
Change (1Y)
11
Growth (1Y)
8.33%
Revenue / Employee
n/a
Profits / Employee
-615.06K GBP
Market Cap
61.42M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 30, 2023 | 143 | 11 | 8.33% |
| Dec 30, 2022 | 132 | 46 | 53.49% |
| Dec 30, 2021 | 86 | 4 | 4.88% |
| Dec 30, 2020 | 82 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 89,900 |
| GSK plc | 70,212 |
| Haleon | 25,408 |
| Smith & Nephew | 18,452 |
| ConvaTec Group | 10,136 |
| Hikma Pharmaceuticals | 9,100 |
| HUTCHMED (China) | 1,988 |
| Oxford Nanopore Technologies | 1,238 |
Adicet Bio News
- 14 days ago - Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones - Business Wire
- 22 days ago - Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma - Business Wire
- 5 weeks ago - Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer - Business Wire
- 2 months ago - Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma - Business Wire
- 2 months ago - Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases - Business Wire
- 2 months ago - Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024 - Business Wire
- 2 months ago - Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates - Business Wire